家族性高胆固醇血症患者管理策略的近况  

The management strategy of Familial hypercholesterolemia patients

作　　者：张筠婷[1] 王绿娅[2] 

机构地区：[1]南华大学附属第一医院,湖南衡阳421001 [2]首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所,北京100029

出　　处：《现代生物医学进展》2008年第8期1553-1556,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金(编号:30470722;30771986和30772356);北京市自然科学基金(编号:7032012;7052021和7062010);北京市科技新星项目(编号:04B27和05A29)联合资助。

摘　　要：家族性高胆固醇血症(FH)是一种常染色体显性遗传性疾病,是脂质代谢疾病中最严重的一种。FH引起动脉粥样硬化(As)病变,导致早期发生较为严重的冠心病(CAD)。初步估计,目前世界范围内FH惠者约10000000例,将其作为重点目标人群进行早期针对性干预对于CAD预防至关重要。FH已经成为世界性健康问题,国外已经制定相应的诊断、治疗指南来规范管理FH患者,而我国这方面的研究工作极为缺乏。因此,制定我国FH患者相应的管理指南迫在眉睫,本文综述FH患者管理相关的研究进展.Familial hypercholesterolemia（FH）is an inherited autosomal dominant disorder of lipoprotein metabolism.It leads to atherosclerosis（As）and early severe coronary artery disease（CAD）.It is preliminarily estimated that there are 10,000,000 FH patients in the world.It is very important to prevention of CAD regarding the FH patients as specific target groups and giving them early intervention.FH has already become a worldwide health problem.Corresponding guides in diagnosis and treatment have set abroad,but at home there are fewer relative reports.So it is extremely urgent to set a guide in diagnosis and treatment to regulate the management of FH patients in China.This paper has reviewed relative research advances on the management of FH patients in the recent years.

关 键 词：家族性高胆固醇血症 管理 指南 

分 类 号：R589.2[医药卫生—内分泌]